NCT06854003 2026-02-20
BRAZAN
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
5 trialsNCT05249959 2026-01-05
FIL_COLUMN
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT07199296 2025-09-30
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Ruijin Hospital
Phase 2 Recruiting
NCT06504199 2024-08-09
ZGR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT04626791 2024-03-12
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Recruiting